Menu

Publications

 

2016

  • G. Milligan, B. Shimpukade, T. Ulven, B. D. Hudson. Complex pharmacology of free fatty acid receptors. Chem. Rev. 2016, doi: 10.1021/acs.chemrev.6b00056.
  • E. Christiansen, B. D. Hudson, A. H. Hansen, G. Milligan, T. Ulven. Development and characterization of a potent free fatty acid receptor 1 (FFA1) fluorescent tracer. J. Med. Chem. 2016, 59(10), 4849-4858.
  • S. V. F. Hansen, E. Christiansen, C. Urban, B. D. Hudson, C. J. Stocker, M. E. Due-Hansen, E. T. Wargent, B. Shimpukade, R. Almeida, C. S. Ejsing, M. A. Cawthorne, M. U. Kassack, G. Milligan, T. Ulven. Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area and Robust in Vivo Efficacy. J. Med. Chem. 2016, 59(6), 2841-2846.
  • M. Grundmann, I. G. Tikhonova, B. D. Hudson, N. J. Smith, K. Mohr, T. Ulven, G. Milligan, T. Kenakin, E. Kostenis, A molecular mechanism for sequential activation of a G protein-coupled receptor. Cell Chem. Biol. 2016, 23, 392-403.
  • S. V. F. Hansen, Z. E. Wilson, T. Ulven, S. V. Ley. Controlled generation and use of CO in flow. React. Chem. Eng. 2016, 1, 280-287.
  • M. E. Due-Hansen, S. Pandey, E. Christiansen, R. Andersen, S. V. F. Hansen, T. Ulven. A protocol for amide bond formation with electron deficient amines and sterically hindered substrates. Org. Biomol. Chem. 2016, 14, 430-433.
  • E. Sergeev, A. H. Hansen, S. K. Pandey, A. E. Mackenzie, B. D. Hudson, T. Ulven, G. Milligan. Non-equivalence of key positively charged residues of the free fatty acid 2 receptor in the recognition and function of agonist versus antagonist ligands. J. Biol. Chem. 2016, 291(1), 303-317.

 

2015

  • S. V. F. Hansen, T. Ulven. Oxalyl chloride as a practical carbon monoxide source for carbonylation reactions. Org. Lett. 2015, 17, 2832-2835. DOI: 10.1021/acs.orglett.5b01252.
  • T. Ulven, E. Christiansen. Dietary fatty acids and their potential for controlling metabolic diseases through activation of FFA4/GPR120. Annu. Rev. Nutr. 2015, 239-263.
  • E. Christiansen, K. R. Watterson, C. J. Stocker, E. Sokol, L. Jenkins, K. Simon, M. Grundmann, R. K. Petersen, E. T. Wargent, B. D. Hudson, E. Kostenis, C. S. Ejsing, M. A. Cawthorne, G. Milligan, T. Ulven. Activity of dietary fatty acids on FFA1 and FFA4 and characterization of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. Br. J. Nutr. 2015, 113, 1677-1688.
  • E. Sokol, T. Ulven, N. J. Færgeman, C. S. Ejsing. Comprehensive and quantitative profiling of lipid species in human milk, cow milk and a phospholipid-enriched milk formula by GC and MS/MSALL. Eur. J. Lipid Sci. Technol. 2015, 117, 751-759.
  • G. Milligan, E. Alvarez-Curto, K. R. Watterson, T. Ulven, B.D. Hudson. Characterising pharmacological ligands to study the long chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4. Br. J. Pharmacol. 2015, 172(13), 3254-3265.

 

2014

  • B. D. Hudson, E. Christiansen, H. Murdoch, L. Jenkins, A. H. Hansen, O. Madsen, T. Ulven G. Milligan. Complex pharmacology of novel allosteric Free Fatty Acid 3 Receptor ligands. Mol. Pharmacol. 2014, 86, 200-210.
  • B. D. Hudson, B. Shimpukade, G. Milligan, T. Ulven. The molecular basis of ligand interaction at free fatty acid receptor 4 (FFA4/GPR120). J. Biol. Chem. 2014, 289, 20345-20358.
  • A. J. Butcher, B. D. Hudson, B. Shimpukade, E. Alvarez-Curto, R. Prihandoko, T. Ulven, G. Milligan, A. B. Tobin. Concomitant action of structural elements and receptor phosphorylation determine arrestin-3 interaction with the free fatty acid receptor FFA4. J. Biol. Chem. 2014, , 289, 18451-18465.
  • K. R. Watterson, B. D. Hudson, T. Ulven, G. Milligan. Treatment of type 2 diabetes by free fatty acid receptor agonists. Front. Endocrinol. 2014, 5, 137.
  • E. Fjaere, U. L. Aune, K. Roen, A. H. Keenan, T. Ma, K. Borokowsky, D. M. Kristensen, G. W. Novotny, T. Mandrup-Poulsen T, B. D. Hudson, G. Milligan, Y. Xi, J. W. Newman, F. G. Haj, B. Liaset, K. Kristiansen, L. Madsen. Indomethacin treatment prevents high-fat diet-induced obesity and insulin resistance, but not glucose intolerance in C57BL/6J mice. J Biol Chem. 2014 Apr 17.
  • G. Milligan, T. Ulven, H. Murdoch, B. D. Hudson. G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets. Br. J. Nutr. 2014, 111, S3-S7.

 

2013

  • B. D. Hudson, B. Shimpukade, A. E. Mackenzie, A. J. Butcher, J. D. Pediani, E. Christiansen, H. Heathcote, A. B. Tobin, T. Ulven, G. Milligan. The pharmacology of a potent and selective agonist, TUG-891, demonstrates both potential opportunity and possible challenges to therapeutic agonism of FFA4 (GPR120). Mol. Pharmacol. 2013, 84, 710-725.
  • B. D. Hudson, M. E. Due-Hansen, E. Christiansen, A. M. Hansen, A. E. Mackenzie, H. Murdoch, S. K. Pandey, R. J. Ward, R. Marquez, I. G. Tikhonova, T. Ulven, G. Milligan. Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J. Biol. Chem. 2013, 288, 17296-17312.
  • E. Christiansen, S. V. F. Hansen, C. Urban, B. Hudson, E. T. Wargent, M. Grundmann, L. Jenkins, M. Zaibi, C. J. Stocker, S. Ullrich, E. Kostenis, M. U. Kassack, G. Milligan, M. A. Cawthorne, T. Ulven. Discovery of TUG-770: A highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes. ACS Med. Chem. Lett. 2013, 4, 441–445.
  • E. Sokol, R. Almeida, H. K. Hannibal-Bach, D. Kotowska, J. Vogt, J. Baumgart, K. Kristiansen, R. Nitsch, J. Knudsen, C. S. Ejsing. Profiling of lipid species by normal-phase liquid chromatography, nanoelectrospray ionization, and ion trap–orbitrap mass spectrometry. Anal. Biochem. 2013, 443, 88–96.
  • B. D. Hudson, H. Murdoch, G. Milligan. Minireview: The effects of species ortholog and SNP variation on receptors for free fatty acids. Mol. Endocrinol. 2013, 27, 1177-1187.
  • B. D. Hudson, T. Ulven, G. Milligan. The Therapeutic Potential of Allosteric Ligands for Free Fatty Acid Sensitive GPCRs. Curr. Top. Med. Chem. 2013, 13, 14-25.
  • Christiansen, M. E. Due-Hansen, C. Urban, M. Grundmann, J. Schmidt, S. V. F. Hansen, B. D. Hudson, M. Zaibi, S. B. Markussen, E. Hagesaether, G. Milligan, M. A. Cawthorne, E. Kostenis, M. U. Kassack, T. Ulven. Discovery of a potent and selective FFA1 agonist with low lipophilicity and high oral bioavailability. J. Med. Chem. 2013, 56, 982-992.

 

2012

  • B. Shimpukade, B. D. Hudson, C. K. Hovgaard, G. Milligan, T. Ulven. Discovery of a potent and selective GPR120 agonist. J. Med. Chem. 2012, 55, 4511-4515.
  • E. Christiansen, M. E. Due-Hansen, C. Urban, M. Grundmann, R. Schröder, B. D. Hudson, G. Milligan, M. A. Cawthorne, E. Kostenis, M. U. Kassack, T. Ulven. Free fatty acid receptor 1 (FFA1/GPR40) agonists: Mesylpropoxy appendage lowers lipophilicity and improves ADME properties. J. Med. Chem. 2012, 55, 6243-6644.
  • B. D. Hudson, E. Christiansen, I. G. Tikhonova, M. Grundmann, E. Kostenis, D. R. Adams, T. Ulven, G. Milligan. Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB J. 2012, 26, 4951-4965.
  • T. Ulven. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front. Endocrinol. 2012, 3, 111, doi:10.3389/fendo.2012.00111.
  • B. D. Hudson, I. G. Tikhonova, S. K. Pandey, T. Ulven, G. Milligan. Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. J. Biol. Chem. 2012, 287, 41195-41209. 

2015

To give you the best possible experience, this site uses cookies Read more about cookies

Accept cookies